Sharing this page with your friends could help raise up to 3x more in donations
Ambien (zolpidem) cannot be obtained online through smart overnight home routes without a valid EPCS prescription from a DEA-registered US healthcare provider, as it is a Schedule IV controlled substance for short-term insomnia treatment only; prescription-free overnight delivery violates 21 U.S.C. § 841 federal felony distribution laws with up to 20-year imprisonment penalties.
Dosing limits to 5mg women/elderly or 10mg men HS with ≥7-8 hours sleep opportunity under 2025 FDA guidelines, with DEA telemedicine flexibilities expiring December 31, 2025 requiring synchronous HIPAA video ISI ≥15 confirmation and PDMP clearance—no smart home route bypasses EPCS or post-flex in-person evaluation mandates.
Zolpidem IR/CR (Ki 25nM), Tmax 1.6h, t½ 2.5h CYP3A4; black box complex sleep behaviors 1-5% (sleep-driving), next-morning impairment OR4 women, dependence 15-25% >4 weeks—discontinue parasomnias, taper 1.25mg weekly; contraindicated severe hepatic impairment, untreated OSA AHI>15, oxybates.
Diagnostic: ISI ≥15 + 3-month sleep diary excluding mimics.
Screening: PDMP clean, Epworth ≤10, negative UDS CNS depressants.
EPCS: #30 tabs 5-10mg zero refills 30 days signature pharmacy delivery.
Monitoring: ≥30% sleep latency reduction q14d + UDS.
| Incidence | Effect Cluster | Risk Factors | Management |
|---|---|---|---|
| 20-40% | Next-day impairment RT>20% | Women 10mg CYP3A4i | 5mg max ≥8h no driving |
| 10-25% | Sleep-driving/eating | Alcohol >10mg | Immediate discontinuation |
| 5-15% | Amnesia >30min | >2 weeks | CBT-I substitution |
| 1-10% | Falls elderly | >65yo | 5mg bed alarms |
| <1% | Respiratory RR<12 | Opioids | Naloxone/CPAP |
Smart overnight home route violates CSA Schedule IV (21 CFR 1306.04), Ryan Haight in-person post-flex (21 USC 802(54)), EPCS mandates—federal felony per shipment.